The Hidden Cost of Waiting to Rescue an At-Risk Clinical Trial

How sponsors can recognize material underperformance, diagnose root causes, and select the least disruptive path to recovery.

Clinical trials rarely move from “on track” to “in crisis” overnight. Warning signs usually emerge gradually: site activation slips, enrollment misses forecast, monitoring falls behind, data queries accumulate, and sponsor teams spend more time resolving operational issues.

Individually, each challenge may appear manageable. Together, they can indicate that a study is moving beyond ordinary execution risk and toward material underperformance.

In rescue engagements, the most consequential issue is often not the first missed milestone, but the time spent addressing symptoms without identifying the underlying causes. The visible costs include extended timelines and higher spending. The hidden cost is the gradual loss of options. As underlying problems persist, sponsors have less time to correct them, fewer practical recovery paths, and greater risk to data quality, internal capacity, and future commercial value.

When Operational Delays Become Commercial Risks

A 2024 Tufts Center for the Study of Drug Development analysis estimated that Phase II and Phase III studies incur approximately $40,000 in direct study-conduct costs per day, rising to $55,716 for Phase III studies. Tufts also estimated that a day of delayed prescription drug or biologic sales represents approximately $800,000 in unrealized revenue on average, although the value varies considerably by product and therapeutic area.

Not every operational delay adds a full day of trial costs or directly postpones commercialization. The figures nevertheless illustrate the value of time in clinical development.

As operational challenges persist, enrollment shortfalls may require added sites, increased monitoring, and expanded vendor support, further increasing costs and operational complexity. Sponsor personnel may also be diverted from other trials and strategic priorities. The consequences extend beyond higher spending. They may include fewer recovery options, declining site engagement, greater risk to data interpretability, and delayed development, financing, or commercial decisions.

When Execution Risk Becomes Rescue Risk

No single metric determines whether a clinical trial requires rescue. Sponsors should look for patterns across enrollment, startup, site performance, data quality, governance, and resource utilization. Four warning patterns deserve particular attention.

Enrollment and Site Activation Repeatedly Fall Behind Plan

Persistent enrollment underperformance may reflect more than an optimistic forecast. Potential causes include ineffective site selection, limited access to the target population, restrictive eligibility criteria, participant burden, low investigator engagement, competing studies, or inconsistent recruitment support.

Adding sites may increase access to potential participants, but it can also add cost and complexity without addressing why current sites are underperforming. Sponsors should first assess performance by country, site, and stage of the participant journey.

A 2024 benchmarking study published in Therapeutic Innovation & Regulatory Science found differences in enrollment achievement by global region and site type. The findings support the importance of using study-specific performance data rather than relying on broad assumptions about site productivity.

Site-activation delays can further increase enrollment risk by reducing productive recruitment time before key milestones. A 2024 WCG presentation reported that the total duration from site identification to study startup averaged 31.4 weeks, approximately one month longer than the average observed a decade earlier. It also cited median activation timelines of 8.12 months for academic medical centers and hospitals, compared with 4.37 months for independent sites and physician practices.

These figures should not be interpreted as universal benchmarks or targets, but they illustrate how site type, institutional requirements, contracting, internal approvals, communication, and operational handoffs can affect activation.

When enrollment or activation repeatedly misses plan, adding sites or extending the timeline should not be the automatic response. Sponsors should first identify whether the primary constraint is site selection, contracting, feasibility, protocol design, participant burden, recruitment support, or operational execution.

Turnover Disrupts Knowledge and Accountability

Turnover among project managers, clinical research associates, data-management personnel, or site staff can lead to inconsistent communication and loss of study knowledge. Delayed follow-up, repeated retraining, unresolved actions, uneven monitoring, and uncertainty about ownership may indicate that the study lacks the continuity and decision-making authority needed to absorb personnel changes.

The primary risk is not simply the number of personnel changes. It is whether documentation, oversight, knowledge transfer, and accountability are strong enough to maintain consistent execution. If responsibilities become fragmented, issues may remain unresolved because each function sees only one part of the study’s overall risk.

Sponsor Oversight Becomes Day-to-Day Management

Escalation is a normal component of clinical trial oversight. A sustained increase in sponsor intervention, however, can indicate that the operating model is no longer working as intended.

Sponsors should take notice when their teams are repeatedly:

• Requesting information that should be routinely available
• Reconstructing performance reports or timelines
• Following up on overdue actions across multiple functions
• Mediating communication between vendors and sites
• Providing day-to-day direction beyond the expected oversight model
• Learning about material risks later than expected

A rising sponsor workload may reveal weaknesses in governance, reporting, resource capacity, or issue management. It also creates an indirect cost that may not be visible in the CRO budget.

The concern is not only the number of hours spent managing the study. It is the opportunity cost of diverting clinical operations and program leadership from other development priorities.

Data-Quality Concerns Threaten Interpretability

Operational recovery is not only about restoring timelines. It must also protect the scientific value of the study.

Inconsistent assessments, monitoring gaps, delayed queries, protocol deviations, missing data, and variability across sites can affect endpoint sensitivity and complicate interpretation. These risks may be especially consequential in indications with heterogeneous outcomes or when endpoint assessments depend on standardized administration.

Additional monitoring or faster query resolution may be necessary, but sponsors should determine whether the underlying issue is training, site capacity, monitoring coverage, technology, protocol feasibility, or endpoint implementation. Some issues can be corrected prospectively. Missing data and inconsistently administered assessments, however, may be difficult or impossible to resolve retrospectively.

What appears to be an isolated data-management issue may therefore signal a broader operational or study-quality problem requiring cross-functional assessment.

Why Tactical Recovery Measures May Fall Short

When a study begins to miss milestones, the initial response is often tactical. Sponsors may add sites, increase recruitment spending, assign new personnel, intensify monitoring, extend timelines, or escalate concerns with the CRO.

These measures may be appropriate, but they are unlikely to produce sustained improvement unless they address the underlying cause.

For example:

• Adding sites will not correct an unrealistic enrollment model or excessively burdensome protocol.
• Increasing recruitment spending will not overcome limited population access, restrictive eligibility criteria, or weak site engagement.
• Adding or replacing personnel will not resolve unclear governance, fragmented accountability, or a structurally under-resourced operating model.
• Extending timelines or changing providers will not improve execution without a clear diagnosis, transition plan, and measurable recovery strategy.

Interventions often fail when they are selected because they are readily available, rather than because they address the study’s primary constraint. A rescue team should be able to explain what action is recommended, which root cause it addresses, what measurable change is expected, and when the sponsor should know whether it is working.

A recovery plan should begin with diagnosis, not activity.

Rescue Does Not Always Mean Replacing the CRO

Full CRO replacement may be appropriate when systemic performance issues, capability gaps, or loss of trust make the current model unsustainable. It is not the only option.

Targeted Overlay Support

A specialized rescue team works alongside the sponsor and incumbent CRO, providing independent assessment, operational leadership, or targeted support in areas such as enrollment, monitoring, data review, governance, and reporting. This model works best when the incumbent CRO retains valuable study knowledge and most functions remain viable.

Hybrid or Functional Transition

In this model, selected responsibilities, such as project management, monitoring, site activation, or data management, transfer to another partner while effective functions remain in place. Success requires clear accountability, decision rights, system access, handoffs, and escalation pathways.

Full CRO Replacement

A complete transition may be necessary when performance problems are systemic. It should be managed as a structured program that protects study knowledge, site relationships, participant safety, regulatory responsibilities, data integrity, system access, and operational continuity.

The central question is not simply whether to replace the CRO. It is which model offers the safest and least disruptive viable path to recovery.

What a Structured Clinical Trial Rescue Strategy Looks Like

Every rescue strategy should reflect the study’s circumstances. An effective approach generally follows four connected stages.

1. Assess

The first step is to establish a reliable view of performance across enrollment, sites, monitoring, data, resources, vendors, budgets, governance, and upcoming milestones.

The assessment should distinguish symptoms from root causes, identify the actions most likely to improve performance, and determine whether the current delivery model can support recovery. Based on these findings, the sponsor can determine whether the study requires targeted overlay support, a functional transition, or a full CRO replacement.

2. Stabilize

Immediate risks may need to be controlled before a broader improvement program can begin.

Stabilization may involve:

• Clarifying ownership and decision rights
• Filling critical resource gaps
• Resetting governance
• Triaging high-risk sites
• Addressing urgent monitoring or data issues
• Establishing dependable reporting and escalation pathways

If responsibilities are being transitioned, ownership of safety, monitoring, data, regulatory submissions, site communications, and investigator payments must remain clear throughout the handoff.

3. Recover and Optimize

Once immediate risks are controlled, the focus can shift to prioritized corrective actions.

These may include reforecasting enrollment, re-engaging sites, strengthening monitoring, resolving vendor dependencies, improving data review, revising recruitment and retention support, or introducing targeted functional expertise.

Progress should be evaluated against defined milestones and performance indicators, not the volume of activity underway.

4. Sustain

A rescue is not successful simply because the first few weeks show improvement. The sponsor needs evidence that the operating model can maintain acceptable performance through study completion.

Leading risk indicators, decision thresholds, governance reviews, and sponsor-ready reporting can help confirm whether progress is sustainable and identify new issues before they become material.

Act While Meaningful Recovery Options Remain

An at-risk trial does not always require a complete operational overhaul. Focused intervention may be sufficient when problems are identified and addressed early. When action is delayed, sponsors may face fewer recovery options, greater disruption, and problems that are increasingly difficult to correct.

Clinical trial rescue is not simply a response to failure. It is a form of risk management that helps sponsors protect study quality, development timelines, internal capacity, and future commercial value.

The hidden cost of waiting is not only what a sponsor spends while a study remains off track. It is what may no longer be recoverable by the time action is taken.

Concerned That a Study May Be Moving Off Track?

You do not need to decide whether to replace your CRO before seeking an objective perspective.

Request a confidential 30-minute clinical trial rescue discussion with P95 Julius Clinical.